Mersana Therapeutics (MRSN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MRSN Mersana Therapeutics

Watchlist

1.980
-0.240-10.81%

Close Nov 21 16:00 ET

2.010
+0.030+1.52%

Post 17:25 ET

244.60MMarket Cap-3300P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Mersana Therapeutics Transferred With Buy Rating at Citi
TipRanksNov 15 05:40 ET · Ratings
Citi Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Cuts Target Price to $5
Moomoo NewsNov 15 05:34 ET · Ratings
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
TipRanksNov 15 05:31 ET · Ratings
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
Moomoo NewsNov 14 23:32 ET · Ratings
A Quick Look at Today's Ratings for Mersana Therapeutics(MRSN.US), With a Forecast Between $6 to $8
Moomoo NewsNov 14 08:00 ET · Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BenzingaNov 13 16:05 ET

Comments

Trytosaveabit

Sep 30 05:11

Watching for this!

$Mersana Therapeutics (MRSN.US)$ Expected to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024

Moomoo AI

Feb 22 13:53

Despite a recent share price hike, Mersana Therapeutics' P/S ratio lags behind others due to forecasted revenue decline. Without major changes, a drastic stock price rise is unlikely.

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 31% But Its Business Still Trails The Industry

Moomoo AI

Dec 20, 2023 06:43

Mersana Therapeutics forecasted future revenue decline contributes to lower P/S ratio, limiting strong rise potential in share prices. The market expects performance drop, keeping P/S suppressed. For P/S to avoid further fall, top-line growth needs improvement.